September 18, 2024
New York — Seborrheic dermatitis (SD) is a common and shared disorder across populations, but it is the third most common dermatologic complaint that Black individuals […]
September 18, 2024
NEW YORK — Underrepresentation by gender and race in major clinical trials has been a cause for complaint for decades, but the US Food and Drug […]
September 18, 2024
TOPLINE: Newborns who go on to develop atopic dermatitis (AD) show higher transepidermal water loss (TEWL) and cord blood serum levels of CCL17/thymus- and activation-regulated chemokine […]
September 17, 2024
TOPLINE: Children with hidradenitis suppurativa (HS) are more likely to have obesity than those without the condition, a review suggests. METHODOLOGY: To evaluate the relationship between […]
September 16, 2024
HUNTINGTON BEACH, California — If the number of recent drug approvals for atopic dermatitis (AD) is overwhelming, the future is unlikely to be any less challenging: […]
September 14, 2024
The US Food and Drug Administration (FDA) has approved the targeted interleukin (IL)-13 inhibitor lebrikizumab (Ebglyss) for the treatment of adults and children age 12 years […]
September 13, 2024
TOPLINE: Primary care patients with predominantly mild psoriasis seldom develop psoriatic arthritis in the shorter term. METHODOLOGY: Investigators analysed data from the TUDOR trial, conducted among […]
September 13, 2024
TOPLINE: In a consensus survey study, participants with atopic dermatitis (AD) agreed on a patient-centered definition of AD flare, which most agreed would help when communicating […]
September 12, 2024
HUNTINGTON BEACH, Calif. — When Roxana Daneshjou, MD, PhD, began reviewing responses to an exploratory survey she and her colleagues created on dermatologists’ use of large […]